|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2005-1-31
|
|
pubmed:abstractText |
Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult-to-treat patient population.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Asthmatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Anti-Idiotypic,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Adrenergic, beta-2,
http://linkedlifedata.com/resource/pubmed/chemical/omalizumab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0105-4538
|
|
pubmed:author |
pubmed-author:AyresJJ,
pubmed-author:BeasleyRR,
pubmed-author:BeehK-MKM,
pubmed-author:BloggMM,
pubmed-author:BousquetJJ,
pubmed-author:CanonicaG WGW,
pubmed-author:FoxHH,
pubmed-author:HébertJJ,
pubmed-author:HedgecockSS,
pubmed-author:HumbertMM,
pubmed-author:RamosSS,
pubmed-author:SlavinRR,
pubmed-author:SurreyKK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
309-16
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15679715-Administration, Inhalation,
pubmed-meshheading:15679715-Adolescent,
pubmed-meshheading:15679715-Adrenal Cortex Hormones,
pubmed-meshheading:15679715-Adrenergic beta-Agonists,
pubmed-meshheading:15679715-Adult,
pubmed-meshheading:15679715-Aged,
pubmed-meshheading:15679715-Anti-Asthmatic Agents,
pubmed-meshheading:15679715-Antibodies, Anti-Idiotypic,
pubmed-meshheading:15679715-Antibodies, Monoclonal,
pubmed-meshheading:15679715-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15679715-Asthma,
pubmed-meshheading:15679715-Dose-Response Relationship, Drug,
pubmed-meshheading:15679715-Double-Blind Method,
pubmed-meshheading:15679715-Drug Therapy, Combination,
pubmed-meshheading:15679715-Female,
pubmed-meshheading:15679715-Forced Expiratory Volume,
pubmed-meshheading:15679715-Humans,
pubmed-meshheading:15679715-Male,
pubmed-meshheading:15679715-Middle Aged,
pubmed-meshheading:15679715-Patient Admission,
pubmed-meshheading:15679715-Quality of Life,
pubmed-meshheading:15679715-Receptors, Adrenergic, beta-2,
pubmed-meshheading:15679715-Retreatment,
pubmed-meshheading:15679715-Severity of Illness Index,
pubmed-meshheading:15679715-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
|
|
pubmed:affiliation |
Hôpital Antoine Beclere, Clamart, France.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|
